Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients With Moderate and Severe Alopecia Areata

NCT06104839 is registered in ClinicalTrials.gov with NEXTGEN Bioscience as lead sponsor.

NCT NCT06104839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06104839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients With Moderate and Severe Alopecia Areata
Lead sponsor
NEXTGEN Bioscience
Phase
Phase 2
Overall status
Recruiting
Start date
September 1, 2024
Completion date
January 31, 2027
Enrollment
73 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata